Rhizopus microsporus as Causative Agent of Mucormycosis in COVID-19 Patient.
Clin Lab
; 68(12)2022 Dec 01.
Article
in English
| MEDLINE | ID: covidwho-2203267
ABSTRACT
BACKGROUND:
The pandemic of coronavirus disease (COVID-19) emerged as a fatal infection, especially in immunocompromised patients. Currently, this infection is managed with systemic corticosteroids. Co-infection of CO-VID-19 with opportunistic fungi is increasingly recognized.METHODS:
We describe a case of rhino-cerebral mucormycosis 12 days following severe COVID-19 in a diabetic patient.RESULTS:
He received 50 mg amphotericin B and surgical debridement. The patient's symptoms improved following medical and surgical intervention.CONCLUSIONS:
Mucormycosis is an uncommon but serious infection that complicates the course of severe COVID-19. Subjects with diabetes mellitus and multiple risk factors may be at a higher risk for developing mucormycosis.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Diabetes Mellitus
/
COVID-19
/
Mucormycosis
Type of study:
Case report
/
Diagnostic study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
/
Male
Language:
English
Journal subject:
Laboratory Techniques and procedures
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS